Add App

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Add App

Property Description
Active ingredient Cyproheptadine hydrochloride
Form Tablet, Syrup (Oral solution)
Pharmacological class First-generation Antihistamine, Serotonin antagonist
General purpose Allergy relief, Appetite support
Origin Synthetic compound

What Type of Medication is Add App?

Add App is the trade reference for a medication whose active ingredient is Cyproheptadine hydrochloride, which is officially classified as a First-generation antihistamine and a powerful Serotonin antagonist. The compound is a synthetic piperidine derivative. This agent possesses the capacity to cross the blood-brain barrier. This structural characteristic differentiates it from newer, non-sedating alternatives, establishing its distinctive profile within the H1-receptor antagonist class.

Composition and Available Forms (Tablet or Syrup)

The medication is a single active ingredient product, composed solely of Cyproheptadine hydrochloride and pharmaceutical excipients. It is strictly an oral systemic agent, absorbed through the digestive system. It is typically available in two presentations for ease of use: a solid tablet and a liquid syrup or oral solution, ensuring flexibility in administration for various patient groups. The availability of the syrup form is particularly beneficial as it enables flexible, precise administration for pediatric patients or those who experience difficulty swallowing.

General Purpose: Dual-Action Relief and Stimulation

The general purpose of Add App is based on its dual mechanism of action, targeting both histamine and serotonin receptors. The medication is utilized to provide general relief of allergic symptoms, while its significant anti-serotonergic activity makes it uniquely suited for offering support in the context of appetite stimulation. This profile underscores its distinct positioning in medical practice, particularly where a sedative effect and appetite support are considered beneficial.

What side effects are possible with Add App?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Cyproheptadine hydrochloride (Add App), based strictly on government regulatory documents.

Key Adverse Reactions and System Involvement

Adverse reactions are classified across several organ systems. Sedation and sleepiness are among the most frequently documented effects, often classified as common. Official regulatory texts note that these primary Central Nervous System (CNS) effects are typically transient and may lessen with continued administration.

Potential effects are listed across multiple System-Organ Classes (SOCs):

System-Organ Class (SOC) Examples of Officially Listed Adverse Reactions
Nervous System Sedation, dizziness, disturbed coordination, convulsions
Gastrointestinal Dryness of mouth, epigastric distress, nausea, constipation
Hepatobiliary Jaundice, hepatic function abnormality, hepatic failure
Cardiovascular Hypotension, palpitation, tachycardia

Serious Adverse Reactions and Safety Constraints

The official safety profile includes documentation of rare but serious adverse reactions, such as convulsions, anaphylactic shock, and potential hepatic failure. Blood dyscrasias are also noted as a rare occurrence with prolonged use.

Explicit safety constraints are defined for certain patient groups. The medicine is officially contraindicated in newborns and premature infants due to the risk of serious effects. Additionally, regulatory information indicates that elderly patients are more likely to experience effects like dizziness, sedation, and hypotension.

Overdose and Emergency Response

The official regulatory profile for Add App (cyproheptadine hydrochloride) overdose describes a spectrum of severe clinical manifestations involving the Central Nervous System (CNS). Presentations can range from profound CNS depression, leading to severe drowsiness and coma, to marked CNS stimulation, which can manifest as excitation, hallucinations, seizures, and convulsions. Specific anticholinergic or "atropine-like" signs are also officially documented, including dry mouth, skin flushing, and fixed, dilated pupils.

Overdose is classified as a potentially severe, life-threatening scenario. Severe outcomes noted in official labeling include cardiorespiratory collapse, specifically respiratory arrest and cardiac arrest, with fatal outcomes having been noted, particularly in pediatric patients. Regulators indicate that pediatric patients may be especially vulnerable to the stimulatory effects and severe outcomes of overdosage.

In the event of a suspected overdose, immediate emergency medical attention is required. Official government guidance mandates contacting emergency services immediately if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Management procedures described in prescribing information include symptomatic and supportive treatment, along with potential interventions like gastric lavage and the use of activated charcoal. Intravenous physostigmine salicylate may be considered by healthcare professionals for managing severe, life-threatening CNS effects.

Therapeutic Uses of Add App

What Add App Treats: Main Uses and Benefits

The therapeutic application of Cyproheptadine (Add App) is relevant in contexts where additional symptomatic support is needed across multiple domains. This medication is commonly used to help ease symptoms related to heightened physiological activity, particularly those associated with allergic reactions.


Symptomatic Support and Management

This medication is used for managing symptom clusters that may become intense or disruptive, especially those related to inflammatory or irritative states. It is commonly used for conditions like chronic urticaria (hives) and generalized pruritus (itching), as well as allergic manifestations such as sneezing, watery eyes, and runny nose. Furthermore, it is applied in addressing poor nutritional status, offering appetite stimulation that assists with maintaining functional stability related to nutritional intake, and may be part of symptomatic management for recurrent migraine headaches.

“This use supports the patient during difficult episodes and contributes to easing the overall symptom load.”

The benefit provided is supportive relief that helps ease the overall symptom burden of chronic skin irritation and allergic reactions, and supports general well-being during symptomatic phases of intense head discomfort or poor appetite.


Quick Fact: Support for Chronic Itching (Pruritus) and Hives (Urticaria)

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The decision to use Add App is based on a careful assessment of its potential benefits against the risk of worsening existing health conditions. This medication is primarily used to treat allergic conditions and to stimulate appetite.

Appropriate Users

Add App is generally suitable for adults and children two years of age and older who require treatment for allergy symptoms or who are experiencing appetite loss. Though generally considered safe for use during pregnancy, it is important to note that the drug may pass into breast milk, making it potentially unsafe for use while breastfeeding.

Patients Who Should Avoid Use (Contraindications)

Add App is contraindicated in patients with specific pre-existing conditions that could be worsened by its effects. These include:

  • Glaucoma (specifically angle-closure).
  • Urinary retention or other issues related to an enlarged prostate or bladder problems.
  • Severe liver disease or stomach ulcers.
  • Current use of Monoamine Oxidase Inhibitors (MAOIs), a class of antidepressant, due to the risk of a dangerous drug interaction.

Use in the elderly should be approached with caution due to the increased risk of side effects like confusion or excessive drowsiness. A healthcare provider must be consulted before starting this or any new medication.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Cyproheptadine hydrochloride (Add App) primarily addresses pharmacodynamic interactions, which involve additive or synergistic effects on the body.

Documented Interaction Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated. This restriction is due to the potential for MAOIs to prolong and intensify the anticholinergic effects of the antihistamine, leading to excessive anticholinergic activity.

Pharmacodynamic Reinforcement

Interactions that result in additive Central Nervous System (CNS) depression are formally documented. Add App may have additive depressant effects when used with alcohol and other CNS depressants, including hypnotics, sedatives, tranquilizers, and antianxiety agents. Furthermore, the drug’s inherent serotonin antagonist activity may cause interference with the effect of serotonin-enhancing antidepressants.

Population-Specific Cautions

Official labeling notes that certain populations are more sensitive to the outcomes of these additive interactions. Elderly or debilitated patients are cited as having an increased susceptibility to adverse effects such as enhanced dizziness, sedation, and hypotension. Conversely, regulatory documents indicate that overdosage, which exacerbates interaction effects, may produce paradoxical stimulation in young children, rather than depression.

Mechanism of Action

The molecular target of Add App is the presynaptic membrane of central nervous system neurons, with selective accumulation in catecholaminergic regions. Its primary action is non-competitive inhibition of the dopamine transporter (DAT) and the norepinephrine transporter (NET). By binding to these transporters, Add App blocks the reuptake of the neurotransmitters dopamine and norepinephrine from the synaptic cleft back into the presynaptic neuron. This blockade results in increased extracellular concentrations of both neurotransmitters, particularly within the prefrontal cortex and striatum. The subsequent prolonged activation of postsynaptic dopamine and adrenergic receptors initiates downstream cascades that modulate cellular excitability. At the system level, this pharmacodynamic effect leads to a net increase in dopaminergic and noradrenergic signaling within key regulatory circuits.

Dosage and Administration Information

How to Use Add App: Official Administration Guidelines

The administration of Cyproheptadine (Add App) is strictly oral, and the total daily dose must be divided and taken throughout the day. This schedule is necessary because the effect of a single dose typically lasts for only four to six hours. The medicine is available as a 4 mg tablet and a 2 mg per 5 mL syrup, which facilitates oral intake, particularly for pediatric patients who may have difficulty swallowing the solid form. It may be administered without regard to meals.

Standard Dosage and Frequency

For adults, the initial dose is typically 4 mg taken three times a day. The daily dosage is then individualized based on patient needs but generally falls within the range of 4 mg to 20 mg per day. The maximum recommended daily intake should not exceed 0.5 mg/kg of body weight.

Population-Specific Use

Established guidelines provide specific dosing maximums for children. For pediatric patients aged 7 to 14 years, the maximum total daily dose is 16 mg. For those aged 2 to 6 years, the maximum daily dose is 12 mg. Dosage for older adults should be selected with caution, initiating treatment at the lower end of the usual adult range due to the greater likelihood of reduced physiological function in this population. If a dose is missed, it is recommended to skip the missed dose and continue with the regular schedule, avoiding a double dose.

Recent Clinical Evidence

Research Evidence Overview: Clinical Studies for Add App

This section provides a summary of the clinical studies that have evaluated the use of Cyproheptadine (Add App), including the types of trials conducted, the populations examined, and the outcomes measured, as documented in regulatory and peer-reviewed scientific literature.


Evidence for Use in Allergic Symptoms and Chronic Urticaria

Research exploring the effects of Cyproheptadine on allergic conditions, such as chronic hives and itching, has been conducted using randomized controlled studies and other controlled clinical studies. These studies focused on outcomes linked to inflammatory or irritative states, including measuring symptom scores for hives and observing patient-reported outcomes describing perceived discomfort. The evidence base includes older, foundational controlled trials that reported measurements of changes in allergic symptom severity over defined time intervals. While evidence from controlled trials exists for its established use, long-term effects are not fully established in recent, high-quality studies, and comparative evidence is lacking against the newest alternative treatments.

Evidence for Appetite Support and Weight Gain

Research explored Cyproheptadine in the context of appetite and various groups with poor nutritional status or growth challenges, particularly in children and adolescents. Studies focused on outcomes reflecting daily functioning or activity level, such as changes in body weight and Body Mass Index (BMI). Studies focusing on specific pediatric cohorts reported how symptoms evolved in the observed populations, but findings were mixed across different populations and underlying chronic conditions. Long-term effects are not fully established, as follow-up durations were limited in many key studies.

Key Limitations and Uncertainty in the Research Landscape

The research landscape for Cyproheptadine is characterized by several limitations. For the established uses, much of the foundational evidence involves older trials where evidence quality varies across studies. Across multiple indications, sample sizes were modest in many key trials, and comparative evidence is lacking against the newest standard treatments. Findings were often mixed or inconsistent, particularly in the case of migraine, where the limited data contributes to low certainty.

Key Studies & References

  1. Cyproheptadine - Drug Information: NIH MedlinePlus
  2. Cyproheptadine for the Prevention of Pediatric Migraine: A Review of the Evidence

Frequently Asked Questions (FAQ)

Common questions about Add App (FAQ)

Q: How does Add App compare to other medicines in the same class?

Regulatory documents indicate that comparative evidence against newer alternative treatments for its established uses is generally lacking. Therefore, official sources do not provide information comparing its effectiveness or safety directly against the most recently approved treatments in the same class.


Q: What makes Add App different from other similar treatments?

Add App, whose active ingredient is Cyproheptadine, is officially classified as both a first-generation antihistamine and a serotonin antagonist. This dual mechanism gives it a distinctive profile and allows it to address both allergy symptoms and appetite stimulation. Furthermore, its chemical structure enables it to cross the blood-brain barrier, which is why it can cause central nervous system effects like drowsiness.


Q: Is Add App considered a new medicine, or has it been around for a while?

The active ingredient in Add App, Cyproheptadine, has been available for a significant period. It is categorized as a Drug Efficacy Study Implementation (DESI)-effective drug, which means it was on the market before 1962 but was later reviewed and found to be effective for its intended uses.


Q: Are the side effects of Add App typically mild or severe?

The most common side effects, such as sedation and sleepiness, are generally reported as transient, meaning they may lessen with continued use. However, the official safety profile includes warnings for rare, serious effects such as hepatic failure (severe liver damage) and convulsions. These serious risks are the reason for cautionary use.


Q: Do most people experience side effects when taking Add App?

Official regulatory documentation lists sedation and sleepiness as 'among the most frequently documented effects.' This indicates these effects are common among users. However, official sources do not provide an exact percentage or prevalence rate to confirm whether 'most people' experience them.


Q: Can Add App affect my mood or mental clarity?

Yes, due to its action on the central nervous system, the medicine may diminish mental alertness, cause dizziness, and affect motor coordination. In young children, it can sometimes produce paradoxical excitation or nervousness, which is an effect opposite to the expected drowsiness.


Q: Will Add App interact with common over-the-counter pain relievers?

Official regulatory documents do not specifically list common over-the-counter pain relievers (like ibuprofen or acetaminophen) as major interactions. However, the medicine has known additive depressant effects with CNS depressants. Due to this, the risk of increased drowsiness must be considered when using it alongside other products that may cause sedation.


Q: Is it safe to take Add App with supplements or vitamins?

Regulatory documents primarily focus on interactions with other prescription medications and alcohol. Interactions with most common dietary supplements or vitamins are generally not explicitly documented in the official labeling.


Q: Are there any specific foods or drinks that should be avoided while using Add App?

Official information states that alcohol should be avoided due to the potential for additive depressant effects, which can increase drowsiness and dizziness. Conversely, the official guidelines state that the medicine may be administered without regard to meals, meaning no specific foods are listed as mandatory to avoid.


Q: How long does it typically take to feel the effects of Add App?

The onset of action for a first dose is generally reported to be approximately 15 to 30 minutes, with peak effects occurring around six to nine hours later.


Q: If I stop using Add App, how long will it stay in my system?

The elimination half-life of the drug's metabolites is approximately 8 to 16 hours. Most of the drug is excreted by the kidneys and in the feces as metabolites.


Q: Are there any known restrictions for people with kidney or liver conditions regarding Add App?

The medicine is generally contraindicated in patients with severe liver disease. Due to the potential for the drug to accumulate with reduced kidney or liver function, official labeling notes that special caution and careful selection of the initial adult dose is suggested.


Q: What is the classification of Add App (e.g., controlled substance, non-narcotic)?

The medicine's active ingredient, Cyproheptadine, is officially classified as a First-generation Antihistamine and a Serotonin Antagonist. It is not classified as a controlled substance under the U.S. Drug Enforcement Administration (DEA).


Q: What is the difference between the brand name and the generic version of Add App?

The difference between the brand name and the generic version is mainly in the inactive ingredients (excipients) or the appearance of the product. However, the FDA requires all generic products to meet the same quality standards and demonstrate bioequivalence to the brand-name product.


Q: Does the generic version of Add App work exactly the same as the brand name?

The FDA requires generic versions to be bioequivalent to the brand-name drug, which means they contain the same active ingredient and work the same way in the body.


Q: Is there a maximum length of time someone should use Add App?

Official labeling does not specify a fixed maximum duration for use. However, regulatory documents note that rare but serious adverse reactions, such as blood dyscrasias (blood disorders), have been associated with prolonged use. Duration of treatment is typically determined by the treating clinician.


Q: Is there a risk of dependence or withdrawal symptoms associated with Add App?

The official labeling does not include warnings for dependence or withdrawal symptoms. The product is not a controlled substance.


Q: Does Add App have a Black Box Warning from the FDA?

No. The official Prescribing Information for Cyproheptadine does not currently contain an FDA Black Box Warning. This type of warning is reserved for drugs that carry the most serious risks.


Q: Why do some people report that Add App is not working for them?

Official research evidence shows that the medicine's effects can be variable. Studies have noted that findings were mixed across different study populations and underlying conditions. This inherent variability in patient response can be a factor in some people not experiencing the intended benefits.


Q: What happens if I accidentally take two doses of Add App?

Taking more than the prescribed amount constitutes an overdose, which can cause symptoms such as extreme drowsiness, confusion, hallucinations, and dilated pupils. In young children, it may cause paradoxical stimulation. Official instructions for overdose scenarios indicate that immediate medical attention is necessary if an overdose is suspected.


Q: Can Add App be taken with medicines for high blood pressure?

Official labeling notes a requirement for caution in patients with cardiovascular disease, including high blood pressure (hypertension). This is due to the drug's potential to cause cardiovascular effects, such as a drop in blood pressure (hypotension).


Q: Why is it important to share my full medical history before using Add App?

A full medical history is necessary for a treating clinician because the medicine is contraindicated in patients with specific pre-existing conditions. These conditions, such as narrow-angle glaucoma, urinary retention, and stomach ulcers, are listed in regulatory documents as potentially being worsened by the drug’s effects.


Q: If I have allergies, can I still take Add App?

While the medicine is prescribed to treat certain allergic symptoms, it is contraindicated (should not be used) if a patient has a known hypersensitivity or allergy to Cyproheptadine itself or any other drugs with a similar chemical structure.


Q: Does the effectiveness of Add App change over time?

Official documents do not specifically address a change in the drug's primary effectiveness over time. However, it is noted that a common side effect, sedation, is typically transient and may lessen with continued administration.


Q: How is the required monitoring for Add App described by regulators?

Due to the risk of rare, serious effects like hepatic failure (liver damage) and blood dyscrasias (blood disorders), the official label notes that monitoring of organ function, such as liver tests and blood counts, may be required by the prescribing clinician, particularly during prolonged use.


Q: What are the ingredients in Add App besides the active drug substance?

Add App is a single-active-ingredient medicine, which means it contains only Cyproheptadine hydrochloride for the intended effect. It also contains several inactive ingredients, or pharmaceutical excipients, which are necessary for the product's stability and form. These can be found listed in the full official Prescribing Information.


Q: Can Add App be crushed or broken?

The official administration guidelines imply that the tablet is typically intended to be swallowed whole. For patients who have difficulty swallowing the tablet, the syrup form is available, which provides a liquid alternative that can be easily measured and swallowed.


Q: What kind of warnings are associated with driving or operating machinery while using Add App?

Official regulatory information includes warnings against engaging in activities requiring complete mental alertness and motor coordination. These activities include driving a car or operating machinery, until an individual is certain how the medicine affects their functioning.

How should Add App be stored and disposed of?

How to Store and Dispose of Add App (Cyproheptadine)

Official regulatory guidelines define specific conditions for storing and disposing of Add App to maintain its stability and prevent accidental exposure.

Requirement Type Official Instructions
Temperature Store at Controlled Room Temperature, between 20 C and 25 C.
Environmental Protection Protect from light and excess moisture. The liquid form (syrup) must not be frozen.
Container Rules Keep the medication in a tightly closed, light-resistant container.
Child Safety Store strictly out of the sight and reach of children.
Disposal Dispose of unused or expired product through an official drug take-back program or by following recommended household disposal steps. Do not flush down the toilet.

The product's stability is maintained when stored within the mandated temperature range and protected from specific environmental constraints. Disposal must follow procedures designed to prevent environmental contamination and accidental ingestion, as specified in regulatory guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Add App found in:

A-Z Index: